Atlas.
Sign inStart free trial
FLGTNASDAQ · US

Fulgent Genetics, Inc.

Technology · Services-Medical Laboratories

TechnologyServices-Medical Laboratories
CEO
Ming Hsieh
Founded
—
IPO Date
—
HQ
El Monte, CA, United States
Exchange
NASDAQ
Employees
n.a.

Share Price Performance

$20.82 ▼ 18.6%
Last (1 Jul 2026) · $21
Period High · $28.65
Period Low · $0.00
52W: $20.82 – $30.85

Key Metrics

Share Price
$20.82
+1.5% today
Market Cap
$644M
P / E
—
EV / Revenue
1.8x
Revenue Growth
+13.8%
year-on-year
Gross Margin
+40.6%
Enterprise Value
$596M
52W High
$30.85
52W Low
$0.00
Avg Volume
473K
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
12 known institutional holders·$91M total on record·2026-Q1
BlackRock, Inc.
9.0%·$44M
Dimensional Fund Advisors LP
2.2%·$11M
Geode Capital Management, LLC
1.9%·$9M
State Street Corp
1.7%·$8M
Jpmorgan Chase & Co
1.5%·$7M
Goldman Sachs Group Inc
1.0%·$5M
Northern Trust Corp
0.6%·$3M
Bank Of America Corp
0.4%·$2M
Invesco Ltd.
0.2%·$905,983
Price T Rowe Associates Inc
0.1%·$425
Renaissance Technologies LLC
0.1%·$286,200
Fmr LLC
0.0%·$12,563
Free Float
81.4%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for Fulgent Genetics, Inc.
OverviewFulgent Genetics, Inc. share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow Fulgent Genetics, Inc. generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsFulgent Genetics, Inc.'s complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityFulgent Genetics, Inc. executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsFulgent Genetics, Inc.'s annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for Fulgent Genetics, Inc., updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for Fulgent Genetics, Inc. aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersFulgent Genetics, Inc. valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for Fulgent Genetics, Inc. with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for Fulgent Genetics, Inc. — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial